Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
REHOVOT, Israel, Feb. 13, 2017 -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the fourth quarter and full year 2016 on Monday, February 27, 2017.
On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-407-2553 toll free from the United States, or +972-3-918-0610 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.
A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-782-4291 toll free from the United States, or +972-3-925-5901 internationally. The replay will be accessible through March 1, 2017, and an archive of the webcast will be available on the Company’s website through March 10, 2017.
About Evogene Ltd.:
Evogene (NASDAQ:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at [email protected].
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact: Karen Mazor, Director Investor Relations E: [email protected] T: +972 54 228 8039
